Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doruk Erkan

Showing results (171-180 of 193) with videos related to

Pageof 20
Sort By:
Arthritis Care & Research|September 28, 2020
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and RepositoryEcem Sevim, Diane Zisa, Danieli Andrade, et al.
The Lancet. Rheumatology|February 1, 2024
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trialEliza F Chakravarty, Tammy Utset, Diane L Kamen, et al.
Lupus|July 25, 2020
Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION RegistryStéphane Zuily, Isabelle Clerc-Urmès, Cédric Bauman, et al.
Advances in Rheumatology (London, England)|October 29, 2021
Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repositoryErivelton de Azevedo Lopes, Gustavo Guimarães Moreira Balbi, Maria G Tektonidou, et al.
Rheumatology (Oxford, England)|October 18, 2024
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry")Irene Cecchi, Massimo Radin, Silvia Grazietta Foddai, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 2, 2023
Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and RepositoryYu Zuo, Sherwin Navaz, Alex Tsodikov, et al.
Rheumatology (Oxford, England)|June 12, 2023
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registryGustavo G M Balbi, Yasaman Ahmadzadeh, Maria G Tektonidou, et al.
Lupus|October 7, 2022
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry")Zeynep B Erton, Rebecca K Leaf, Danieli de Andrade, et al.
Seminars in Arthritis and Rheumatism|June 3, 2019
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohortMassimo Radin, Savino Sciascia, Doruk Erkan, et al.
Arthritis Care & Research|July 7, 2025
Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of DefinitionsMedha Barbhaiya, Stephane Zuily, Deanna Jannat-Khah, et al.
Pageof 20

Showing results (171-180 of 193) with videos related to

Sort By:
Pageof 20
Arthritis Care & Research|September 28, 2020
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and RepositoryEcem Sevim, Diane Zisa, Danieli Andrade, et al.
The Lancet. Rheumatology|February 1, 2024
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trialEliza F Chakravarty, Tammy Utset, Diane L Kamen, et al.
Lupus|July 25, 2020
Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION RegistryStéphane Zuily, Isabelle Clerc-Urmès, Cédric Bauman, et al.
Advances in Rheumatology (London, England)|October 29, 2021
Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repositoryErivelton de Azevedo Lopes, Gustavo Guimarães Moreira Balbi, Maria G Tektonidou, et al.
Rheumatology (Oxford, England)|October 18, 2024
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry")Irene Cecchi, Massimo Radin, Silvia Grazietta Foddai, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 2, 2023
Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and RepositoryYu Zuo, Sherwin Navaz, Alex Tsodikov, et al.
Rheumatology (Oxford, England)|June 12, 2023
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registryGustavo G M Balbi, Yasaman Ahmadzadeh, Maria G Tektonidou, et al.
Lupus|October 7, 2022
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry")Zeynep B Erton, Rebecca K Leaf, Danieli de Andrade, et al.
Seminars in Arthritis and Rheumatism|June 3, 2019
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohortMassimo Radin, Savino Sciascia, Doruk Erkan, et al.
Arthritis Care & Research|July 7, 2025
Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of DefinitionsMedha Barbhaiya, Stephane Zuily, Deanna Jannat-Khah, et al.
Pageof 20